ContextLogic Inc. (LOGC)
| Market Cap | 188.64M |
| Revenue (ttm) | 7.00M |
| Net Income (ttm) | -20.00M |
| Shares Out | 26.68M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,666,922 |
| Average Volume | 918,694 |
| Open | 6.60 |
| Previous Close | 6.68 |
| Day's Range | 6.54 - 6.97 |
| 52-Week Range | 4.92 - 9.34 |
| Beta | 2.03 |
| RSI | 44.06 |
| Earnings Date | Aug 8, 2025 |
About ContextLogic
ContextLogic Inc. does not have significant operations. It focuses on identifying, evaluating, and executing strategic opportunities. Previously, it was engaged in the marketplace and logistics business operations. ContextLogic Inc. was incorporated in 2010 and is headquartered in Oakland, California. [Read more]
Financial Performance
In 2024, ContextLogic's revenue was $43.00 million, a decrease of -85.02% compared to the previous year's $287.00 million. Losses were -$75.00 million, -76.34% less than in 2023.
Financial StatementsNews
ContextLogic to voluntarily delist from Nasdaq, move to OTCQB Market
ContextLogic Inc. to Commence Trading on the OTC Markets and Delist from Nasdaq
OAKLAND, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC) (“ContextLogic,” the “Company,” “we” or “our”) today announced its intention to voluntarily delist from The Nasdaq Gl...
ContextLogic Inc (LOGC) Q1 2025 Earnings Call Highlights: Strategic Investments Propel Growth ...
ContextLogic Inc (LOGC) Q1 2025 Earnings Call Highlights: Strategic Investments Propel Growth Prospects
ContextLogic outlines $222M cash reserves and future acquisition potential
ContextLogic Inc. (LOGC) Q1 2025 Earnings Call Transcript
ContextLogic GAAP EPS of -$0.27 misses by $0.19
ContextLogic Inc. Reports First-Quarter 2025 Financial Results
OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter ended March 31, 2...
ContextLogic Q1 2025 Earnings Preview
An Overview of ContextLogic's Earnings
ContextLogic (NASDAQ: LOGC) is gearing up to announce its quarterly earnings on Friday, 2025-05-09. Here's a quick overview of what investors should know before the release. Analysts are estimating t...
ContextLogic to Announce First Quarter 2025 Results on May 9, 2025
OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic” or the “Company”) today announced it will report its first quarter 2025 financial results after the ...
ContextLogic Inc. (WISH) Q4 2024 Earnings Conference Call Transcript
ContextLogic Inc. (WISH) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Ted Goldthorpe - Chairman Rishi Bajaj - CEO Conference Call Participants Operator Good afternoo...
ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results
OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and fiscal year...
ContextLogic to Announce Fourth Quarter and Full Year 2024 Results and Provide Strategic Update on March 12, 2025
OAKLAND, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic,” the “Company,” “we” or “our”) today announced it will report its fourth quarter and full year 202...
ContextLogic Inc. Reports Third-Quarter 2024 Financial Results
OAKLAND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and nine months...
ContextLogic Inc. Reports Second-Quarter Financial Results
OAKLAND, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and six months ...
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine ...
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality w...
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.
INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC
NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rat...
SHAREHOLDER ALERT: Weiss Law Investigates LogicBio Therapeutics, Inc.
NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of LogicBio Therapeutics, Inc. ("LogicBio" ...
Shareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its transaction with AstraZeneca
MILWAUKEE , Oct. 3, 2022 /PRNewswire/ -- Ademi LLP is investigating LogicBio (NASDAQ: LOGC) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca. Cl...
LogicBio's stock skyrockets after buyout bid for a 667% premium
Shares of LogicBio Therapeutics Inc. LOGC, +641.32% skyrocketed more than seven-fold (up 643%) in morning trading, to bounce off the previous session's record low, after the genetic medicine company a...
LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) to AstraZeneca Rare Disease for $2.07 per shar...
AstraZeneca pays 660% premium for gene therapy firm LogicBio
Shares of LogicBio Therapeutics skyrocketed on Monday after Britain's AstraZeneca's said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ:...